Why the GIP receptor makes Mounjaro different from other weight-loss injections

You've been told it works on two hormones, here's what that actually feels like in practice

Imagine eating a meal and feeling genuinely satisfied after a normal portion rather than just less hungry. That distinction matters. GLP-1 receptor agonists reduce appetite by signalling fullness and slowing the rate at which food leaves the stomach. That is real and clinically meaningful. But GIP receptor activation appears to add something different: a modulation of how the brain processes the reward signal of eating, and a direct effect on how fat tissue responds to energy signals. The result, in practice, is that people on tirzepatide often report a change not just in how much they eat, but in how food feels, less preoccupying, less urgent.

This isn't a marketing description. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes across tirzepatide doses and placebo over 72 weeks. The 15 mg group saw an average body-weight reduction of around 20–21%. That figure sits well above what GLP-1-only trials consistently produced at equivalent timepoints, which is what prompted researchers to look more closely at what GIP receptor co-activation was contributing.

For most people reading this, the practical question isn't the molecular pathway, it's whether the results justify the treatment. The trial data suggest they do, at clinically meaningful scale. If you're wondering whether a doctor can prescribe Mounjaro for you and what that process involves, a prescriber reviewing your full health picture can help you understand where that evidence applies to your situation. Our clinical team works through exactly that during consultation.

What the GIP receptor is actually doing (and why researchers were initially unsure it would help

GIP) glucose-dependent insulinotropic polypeptide, was identified decades ago as an incretin hormone: it tells the pancreas to release insulin after a meal. For years, researchers assumed activating the GIP receptor would simply add to GLP-1's insulin-stimulating effects, making tirzepatide useful mainly for blood sugar. The fat-tissue and brain findings were less expected.

GIP receptors sit in adipose tissue, where they appear to influence how fat cells store and release energy. They're also expressed in brain regions involved in appetite regulation and in the central nervous system's response to eating. When both receptor types are activated together, the effect on appetite and body weight appears to be greater than either pathway produces alone, what researchers describe as synergistic rather than simply additive.

That said, unpicking exactly how much each receptor contributes is genuinely difficult in humans, because you can't simply turn one off in a live trial. The BNF's tirzepatide monograph describes tirzepatide as a dual GIP and GLP-1 receptor agonist and notes its distinct pharmacodynamic profile; the mechanism is accepted, the precise weighting of each receptor's contribution remains an active area of research. Honest science acknowledges that.

What the clinical data show clearly is the output: weight loss at a scale not previously seen with injectable GLP-1 medicines, sustained across a large trial population. Understanding how tirzepatide differs from older treatments helps explain why those results look the way they do. If you're curious how emerging treatments like retatrutide compare, the field is moving toward even broader receptor targeting, though none of those options are licensed in the UK yet.

How GIP receptor action changes what Mounjaro's side-effect profile looks like

One of the more clinically interesting consequences of dual-receptor activity is that GIP receptor activation appears to reduce some of the gastrointestinal side effects that GLP-1-only medicines produce. The exact mechanism isn't fully established, but GIP may partially offset the gastric-emptying slowdown that GLP-1 signalling causes, which is why tirzepatide's GI tolerability data in the SURMOUNT trials were somewhat better than clinicians expected given the degree of weight loss achieved.

That doesn't mean Mounjaro is side-effect-free. Nausea, diarrhoea, constipation and fatigue remain the most commonly reported effects, particularly in the first weeks of treatment and after dose increases. They're the same category of symptoms as GLP-1 medicines, just (on average) reported as less severe by trial participants. Individual experience varies considerably, and the Patient Information Leaflet (available via the eMC) is the definitive reference for what to watch for.

Injection-site reactions are also possible; rotating between the abdomen, thigh and upper arm reduces localised irritation. Storage is refrigerated at 2–8°C, with a limited room-temperature window detailed in the leaflet. And because Mounjaro is a Black Triangle (▼) medicine under additional MHRA monitoring, reporting any suspected side effect through the Yellow Card scheme contributes to the ongoing safety evidence base.

For anyone thinking about how treatment costs fit into this, an overview of what's included in private treatment through a regulated pharmacy is worth reading before making any decision.

GIP, GLP-1, and the bigger picture for people weighing up treatment options

The dual-receptor question often comes up when people are comparing Mounjaro to Wegovy, or reading about next-generation compounds. It's a fair thing to interrogate. Both Mounjaro and Wegovy are licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with a qualifying weight-related condition. Their mechanisms differ. Their trial results differ. Which is clinically appropriate for a given person depends on their medical history, current medicines, any contraindications and their prescriber's assessment, not on which headline weight-loss figure looks more appealing.

If you're investigating how newer dual or triple-agonist molecules compare to tirzepatide, the GIP receptor is central to that story too, amycretin, for example, adds an amylin pathway on top of GLP-1, while retatrutide adds glucagon. The receptor combinations keep expanding. People who are deciding between options sometimes find it helpful to read through a comparison of retatrutide and Mounjaro before speaking to a prescriber, and for now, Mounjaro remains the only dual GIP/GLP-1 medicine licensed for weight management in the UK, so understanding what makes that combination distinct is genuinely useful context before a clinical conversation.

A broader look at how Mounjaro works and who it's licensed for covers the eligibility picture in full. Our prescribers review every consultation individually (the same day it's submitted) and can work through your specific questions with the kind of detail a product page can't replicate. Some people also find it useful to understand what a typical Mounjaro treatment plan looks like in practice, including how doses are structured over time.